SOPHiA DDM™ deep-learning algorithm will
help determine HRD status of tumors for Institute of Oncology
Ljubljana researchers
BOSTON and LAUSANNE, Switzerland, May 24, 2023
/PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native
software company in the healthcare space and a leader in
data-driven medicine, today announced that the Institute of
Oncology Ljubljana (IOL), a comprehensive public institution
for detection, treatment and research of cancer, based in
Ljubljana, Slovenia, is live on
SOPHiA DDM™. To help advance its clinical oncology research, IOL is
leveraging low-pass Whole Genome Sequencing (WGS) data computed by
the proprietary GIInger deep-learning algorithm from SOPHiA
GENETICS to increase research efficiency and obtain actionable
clinical insights to make data-driven decisions that improve the
quality of patient care.
IOL will use SOPHiA DDM™ to identify Homologous Recombination
Deficiency (HRD) in tumor samples. HRD is when a cell is unable to
repair double-stranded breaks, which can lead to the accumulation
of genomic scars. HRD is a common feature of high-grade serous
ovarian cancer (HGSOC) as well as breast, prostate, and pancreatic
cancers, and can be used as a potential predictive biomarker for
therapy response.
"As the leading institution in the country for the detection,
treatment and research of cancer, we work to ensure balanced and
proper development of oncology health services. This is why
research and education hold a special position at the Institute,"
said Dr. Srdjan Novaković, DSc (Biol.), Head of the Department of
Molecular Diagnostic, Institute of Oncology Ljubljana. "With the
support of SOPHiA GENETICS, our researchers will be able to
expedite testing and analysis associated with the determination of
HRD, helping to facilitate faster clinical decision-making and
advance cancer research in Slovenia."
IOL will use the SOPHiA DDM™ Platform, which offers an
application that is capable of combining information from germline
and somatic homologous recombination repair (HRR) mutations,
including BRCA1 and BRCA2, with a measure of genomic
scarring. Through this approach, users can obtain reliable and
fast, in-house data. HRR is a cellular process that repairs
double-stranded breaks (DSB) arising from the DNA replication
process or resulting from exposure to DNA-damaging agents.
"Our work at SOPHiA GENETICS is to democratize data-driven
medicine," said Esteban Czwan, Managing Director, EMEA, SOPHiA
GENETICS. "The SOPHiA DDM™ Platform will support the Institute
of Oncology Ljubljana to gain comprehensive genomic insights
powered by deep learning algorithms, leading to data-driven
conclusions, while helping them increase efficiency and volume of
profiles analyzed."
With the cloud-based SOPHiA DDM™ Platform, the Institute of
Oncology Ljubljana will amass an in-house database that will
help to further their cancer research and progress for all of
Slovenia.
For more information on SOPHiA GENETICS,
visit SOPHiAGENETICS.COM, or connect
on Twitter, LinkedIn, Facebook, and Instagram.
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a software company dedicated to
establishing the practice of data-driven medicine as the standard
of care and for life sciences research. It is the creator of the
SOPHiA DDM™ Platform, a cloud-native platform capable of analyzing
data and generating insights from complex multimodal data sets and
different diagnostic modalities. The SOPHiA DDM™ Platform and
related solutions, products and services are currently used by a
broad network of hospital, laboratory, and biopharma institutions
globally. For more information, visit SOPHiAGENETICS.COM, or
connect on Twitter, LinkedIn, Facebook,
and Instagram. Where others see data, we see
answers.
SOPHiA DDM™ Dx Homologous Recombination Deficiency
Solution is available as a CE-IVD product for In Vitro Diagnostic
Use in Europe, Turkey, and Slovenia. The information in this
press release is about products that may or may not be available in
different countries and, if applicable, may or may not have
received approval or market clearance by a governmental regulatory
body for different indications for use. Please contact
support@sophiagenetics.com to obtain the appropriate product
information for your country of residence.
SOPHiA GENETICS Forward-Looking Statements:
This press release contains statements that constitute
forward-looking statements. All statements other than statements of
historical facts contained in this press release, including
statements regarding our future results of operations and financial
position, business strategy, products, and technology, as well as
plans and objectives of management for future operations, are
forward-looking statements. Forward-looking statements are based on
our management's beliefs and assumptions and on information
currently available to our management. Such statements are subject
to risks and uncertainties, and actual results may differ
materially from those expressed or implied in the forward-looking
statements due to various factors, including those described in our
filings with the U.S. Securities and Exchange Commission. No
assurance can be given that such future results will be achieved.
Such forward-looking statements contained in this press release
speak only as of the date hereof. We expressly disclaim any
obligation or undertaking to update these forward-looking
statements contained in this press release to reflect any change in
our expectations or any change in events, conditions, or
circumstances on which such statements are based, unless required
to do so by applicable law. No representations or warranties
(expressed or implied) are made about the accuracy of any such
forward-looking statements.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/institute-of-oncology-ljubljana-leverages-sophia-ddm-platform-for-cancer-research-301832897.html
SOURCE SOPHiA GENETICS